After months of speculation, it has finally been announced that Royal Bank of Scotland(LSE: RBS) (NYSE: RBS.US) chairman Sir Philip Hampton will step down from his role to take up the same job at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).
This is a major loss for RBS, since Sir Philip Hampton has guided the bank through a very dark period in its history and has successfully helped it to be on course to return to profitability in the current year. With GlaxoSmithKline having endured a period of negative sentiment resulting from bribery allegations, is he the man to turn the companys fortunes around? More importantly, should you and your money follow him from RBS to GlaxoSmithKline?
Although shares in the two companies have delivered disappointing performances over the last year (RBS is down 2% and GlaxoSmithKline is down 10%), they both have considerable future potential.
In GlaxoSmithKlines case, this centres around its drugs pipeline. Indeed, while many of its sector peers notably AstraZeneca have struggled to come to terms with the loss of exclusivity on key blockbuster drugs, GlaxoSmithKline continues to have a diverse and highly attractive pipeline.
Furthermore, with the sale of the companys consumer goods businesses, Ribena and Lucozade, GlaxoSmithKline has become a pure play pharmaceutical stock that is intent on focusing all of its resources on the future development of new drugs. This bodes well for the companys top and bottom lines, as well as for its shareholders.
Meanwhile, RBS has a bright future, too. As mentioned, its bottom line is due to return to being in the black this year, with the banks strategy being a major reason for this. Overseen by Sir Philip Hampton and Stephen Hester (followed by current CEO Ross McEwen), RBS has gradually reduced the size of its balance sheet through a number of disposals. This has left the bank leaner, less risky and, in the long run, better positioned to generate increasing profits.
Clearly, Sir Philip Hampton has been a key part of the RBS turnaround story. While RBS being on course to post pre-tax profits of 5.2 billion for the full year is perhaps taken for granted today, it has been a superb turnaround from the last five years when the bank lost around 17.8 billion in total. As such, he is likely to prove to be a major asset at GlaxoSmithKline, which bodes well for investors in the stock and undoubtedly makes it a more attractive investment opportunity.
As for whether RBS is now a sell, although there is still more progress to be made, the bank is well on the way to recovery. While market sentiment remains weak, with RBS trading on a price to book ratio of just 0.4, it has a bright future and appears to be well worth buying at current price levels.
Of course, RBS and GlaxoSmithKline aren’t the only companies that could give your portfolio a boost. So, which other shares should you buy, and why?
A great place to start is a free and without obligation guide from The Motley Fool called Where We Think The Smart Money Is Headed.
The guide is simple, clear and actionable. It could help you to uncover a number of hidden gems and make 2014 and beyond an even more prosperous period for your investments.
Click here to obtain your copy of the guide – it’s completely free and comes without any further obligation.
Peter Stephens owns shares of RBS, GlaxoSmithKline and AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.